Roche Holding | ROG - Zahlungsmittel Und Äquivalente





Zahlungsmittel Und Äquivalente Veränderung Datum
AbbVie USD 10.77B 4.2B 2026-09
Alcon AG USD 1.58B 80M 2026-03
Almirall EUR 354.57M 16.8M 2026-06
Amgen USD 13.19B 799M 2026-09
AstraZeneca USD 4.89B 2.67B 2026-06
Bayer EUR 4.29B 1.44B 2026-06
Biogen USD 1.3B 18.9M 2026-09
Bristol-Myers Squibb USD 9.57B 852M 2026-09
Eli Lilly USD 4.89B 4.07B 2026-09
Fresenius EUR 1.28B 780M 2026-06
Fresenius Medical Care EUR 1.1B 37.86M 2026-09
Genmab DKK 1.5B 18M 2026-06
Gilead Sciences USD 3.18B 4.45B 2026-06
GlaxoSmithKline GBP 3.1B 337M 2026-06
GRIFOLS EUR 486M 27M 2026-09
Hikma Pharmaceutical USD 217M 19M 2025-12
Lakefront Biotherapeutics EUR 135.95M 69.15M 2026-06
Lonza CHF 719M 188M 2025-12
Merck EUR 2.74B 415M 2026-03
Merck USD 9.55B 2.7B 2026-09
Novartis USD 8.87B 1.25B 2026-09
Orion EUR 144.3M 55M 2026-09
Pfizer USD 1.82B 848M 2026-09
Philips EUR 2.75B 962M 2026-09
Recordati EUR 391.38M 10.92M 2026-06
Regeneron Pharmaceuticals USD 3.66B 1.2B 2026-09
Roche Holding CHF 7.55B 579M 2025-06
Sanofi EUR 6.35B 806M 2026-06
UCB EUR 1.57B 1.14B 2024-12